首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1657333

疫苗注射設備市場 - 全球產業規模、佔有率、趨勢、機會和預測，按設備、按給藥途徑、按地區和競爭進行細分，2020-2030 年預測

Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device, By Route Of Administration, By Region and Competition, 2020-2030F

出版日期: 2025年02月17日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球疫苗輸送設備市場價值為 78.6 億美元，預計到 2030 年將達到 118.8 億美元，預測期內複合年成長率為 7.08%。全球疫苗輸送設備市場主要受到全球對疫苗的需求不斷成長的推動，特別是考慮到 COVID-19 大流行和全球對免疫計劃的需求不斷成長。無針裝置、微針和自動注射器等疫苗輸送技術的進步正在提高疫苗接種的有效性和便利性。傳染病和慢性病發病率的上升以及預防性醫療保健的需求進一步推動了市場的成長。政府推動疫苗接種運動的措施（尤其是在新興市場）促進了對高效和安全的疫苗接種系統的需求。提高針頭安全性、減輕疼痛和增強患者依從性的技術創新也是推動市場向前發展的關鍵因素，同時也提高了全球醫療保健的機會和意識。

市場概況
預測期	2026-2030
2024 年市場規模	78.6 億美元
2030 年市場規模	118.8 億美元
2025-2030 年複合年成長率	7.08％
成長最快的領域	注射器
最大的市場	北美洲

主要市場促進因素

全球疫苗接種需求上升

預防保健日益受到重視

傳染病發生率上升

全球旅行和移民增加

個人化疫苗接種的新興技術

擴大新興市場的醫療基礎設施

主要市場挑戰

先進疫苗注射裝置成本高昂

物流和配送挑戰

技術限制和相容性問題

主要市場趨勢

輸送設備的技術進步

政府措施和資金

分段洞察

設備洞察

給藥途徑洞察

區域洞察

Global Vaccine Delivery Devices Market was valued at USD 7.86 Billion in 2024 and is expected to reach USD 11.88 Billion by 2030 with a CAGR of 7.08% during the forecast period. The Global Vaccine Delivery Devices Market is primarily driven by the increasing global demand for vaccines, particularly in light of the COVID-19 pandemic and the growing need for immunization programs worldwide. Advancements in vaccine delivery technologies, such as needle-free devices, microneedles, and auto-injectors, are enhancing the effectiveness and ease of vaccine administration. The rising prevalence of infectious diseases, chronic conditions, and the need for preventive healthcare further fuel market growth. Government initiatives promoting vaccination campaigns, particularly in emerging markets, contribute to the demand for efficient and safe vaccine delivery systems. Technological innovations improving needle safety, reducing pain, and enhancing patient compliance are also key factors driving the market forward, along with increasing healthcare access and awareness globally.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 7.86 Billion
Market Size 2030	USD 11.88 Billion
CAGR 2025-2030	7.08%
Fastest Growing Segment	Syringes
Largest Market	North America

Key Market Drivers

Rising Global Vaccination Demand

The increasing global demand for vaccines is one of the most significant drivers for the growth of the vaccine delivery devices market. The urgency surrounding immunization has intensified due to the outbreak of pandemics like COVID-19 and the ongoing efforts to combat global infectious diseases such as influenza, measles, and human papillomavirus (HPV). With governments, healthcare organizations, and NGOs working collaboratively to expand vaccination coverage, the global population's vaccination rates have been rising steadily. The focus on universal health coverage (UHC), especially in developing economies, has been instrumental in improving access to vaccines. This increase in demand for vaccines directly correlates with a greater need for efficient, user-friendly delivery devices, as mass immunization campaigns require technologies that can facilitate quick, widespread, and safe administration of vaccines. Research indicates that global coverage for the third dose of the diphtheria, tetanus, and pertussis (DTP3) vaccine has shown an uneven recovery from COVID-related disruptions, reaching 81% in 2022, up from 79% in 2021.

Given the rising awareness of the importance of preventive healthcare and growing disease outbreaks, the urgency for administering vaccines across various age groups and geographic locations has fueled the market for vaccine delivery devices. The surge in vaccine-related demand due to initiatives like Global Vaccine Safety Initiative by the World Health Organization (WHO) and partnerships among pharmaceutical companies and governments worldwide continues to propel the growth of this market, as delivery devices must evolve to meet both global demand and higher expectations for patient safety and comfort.

Growing Focus on Preventive Healthcare

As the focus on preventive healthcare continues to grow, vaccines are increasingly seen as the first line of defense against numerous diseases. Global health organizations and governments are prioritizing vaccination as an essential element in the prevention of infectious diseases, including polio, HIV, hepatitis, and influenza. This growing emphasis on preventive care is propelling the adoption of vaccines across a wide range of demographics. With vaccines being developed for chronic conditions and lifestyle diseases such as cervical cancer and HPV, the market for vaccine delivery devices is expanding to meet the needs of new patient populations. In August 2022, GSK plc completed the acquisition of Affinivax, Inc., a Cambridge-based clinical-stage biopharmaceutical company focused on innovative vaccines. This acquisition strengthens GSK's strategy to expand its portfolio of specialty medicines and vaccines. It includes AFX3772, a next-generation 24-valent pneumococcal vaccine currently in Phase II trials, along with a 30-plus valent vaccine in preclinical development. These strategic moves enhance operational efficiency and accelerate innovation, fostering competition and growth within the industry.

The global movement towards health promotion and wellness is also boosting vaccine adoption, especially in developed countries where public health campaigns promote vaccines as part of a holistic approach to long-term health. These public health strategies significantly contribute to the increased volume of vaccine administrations, which in turn fuels the demand for delivery devices.

Rising Prevalence of Infectious Diseases

The rise in the prevalence of infectious diseases globally continues to drive the market for vaccine delivery devices. Outbreaks of infectious diseases, such as COVID-19, Ebola, diphtheria, malaria, and measles, highlight the need for effective and rapid vaccine delivery. In response, both developed and emerging economies are ramping up immunization efforts. Vaccine delivery devices that can ensure safe, efficient, and large-scale vaccine administration are critical in responding to these threats. With disease outbreaks becoming more frequent due to factors such as globalization, climate change, and urbanization, the role of vaccination and effective delivery mechanisms is even more pronounced. In 2022, over 15,770 deaths in Australia were linked to infectious diseases, representing a rate of 61 per 100,000 people. Approximately one-third (33%) of these deaths were caused by non-notifiable diseases, with lower respiratory infections being the most prevalent, accounting for nearly 2,594 deaths or 10 per 100,000.

The World Health Organization (WHO) and other health organizations continue to push for universal immunization, particularly in high-risk regions, to reduce the burden of infectious diseases. These efforts contribute to the expansion of the vaccine delivery devices market as new and improved technologies are required to reach millions of people efficiently.

Increase in Global Travel and Migration

With an increase in global travel, migration, and the interconnectivity of nations, the spread of infectious diseases has become more prevalent, requiring comprehensive vaccination strategies. People moving across borders for work, tourism, and education create potential vectors for disease transmission, making widespread vaccination essential to prevent pandemics. The growing number of international travelers and migrant populations heightens the need for mass immunization campaigns to protect individuals from diseases such as yellow fever, tuberculosis, and influenza. Vaccine delivery devices play a key role in enabling swift and efficient immunization, particularly at airports, border crossings, and public health vaccination sites, thereby supporting the prevention of cross-border disease spread.

Emerging Technologies in Personalized Vaccination

The increasing shift towards personalized medicine is also contributing to the growth of the vaccine delivery devices market. Genomic-based vaccinations are a growing area of research, and with this shift comes the need for delivery systems that can accommodate new types of vaccines, including those tailored to an individual's genetic profile. Personalized vaccination regimens, such as those targeting specific viral strains or mutations, will require innovative delivery devices to ensure targeted and effective administration. These developments in biotechnology are driving the need for new delivery systems that are capable of handling a wide variety of vaccine types. In January 2022, Pfizer Inc. and Acuitas Therapeutics formed a strategic partnership to jointly develop a lipid nanoparticle delivery system tailored for mRNA vaccines and therapeutics. This collaboration seeks to combine the expertise of both companies to improve the delivery efficiency and effectiveness of mRNA-based vaccines and treatments.

Expanding Healthcare Infrastructure in Emerging Markets

The expansion of healthcare infrastructure in emerging markets such as Asia-Pacific, Africa, and South America is a vital driver of the vaccine delivery devices market. As these regions improve healthcare access, vaccination programs are being rolled out to broader populations. Vaccine delivery devices are crucial in this context, as they ensure that vaccines are administered safely and effectively. With increasing investments in healthcare infrastructure and more robust distribution networks, emerging economies are adopting advanced vaccine delivery technologies that improve the efficiency and effectiveness of immunization campaigns. Government-backed initiatives and international partnerships are supporting the development and accessibility of innovative delivery systems to meet the growing demand for vaccines in these regions.

Key Market Challenges

High Cost of Advanced Vaccine Delivery Devices

One of the significant challenges facing the vaccine delivery devices market is the high cost associated with advanced delivery technologies, such as needle-free systems and microneedles. While these technologies offer enhanced comfort, safety, and patient compliance, they often come with higher production and development costs compared to traditional syringe-based systems. For countries with limited healthcare budgets or in regions where cost-effectiveness is paramount, the adoption of these advanced devices can be prohibitive. While these devices may offer long-term benefits in terms of efficiency and patient acceptance, the initial investment may deter some governments or organizations from embracing them, especially in low- and middle-income countries. Overcoming these cost barriers is essential to ensure that these innovative delivery systems can be scaled for global use.

Logistical and Distribution Challenges

The distribution of vaccines and vaccine delivery devices, especially in remote or underserved areas, remains a major challenge. The cold storage requirements for many vaccines, coupled with the complexity of ensuring that vaccines are administered using the proper delivery devices, require sophisticated logistics systems. In low-resource regions, limited access to advanced infrastructure, such as cold chain systems, can result in challenges related to the safe and timely delivery of vaccines

For new delivery devices, ensuring that they are available where they are most needed-whether in remote villages, refugee camps, or health centers in developing nations-requires significant investment in infrastructure, education, and supply chain management.

Technical Limitations and Compatibility Issues

While technological advancements in vaccine delivery devices have greatly improved their efficacy, there are still technical limitations that can hinder their widespread adoption. For example, needle-free devices may not be suitable for all types of vaccines or for every patient. Certain vaccines require precise delivery under controlled conditions, and these systems may not always offer the same level of accuracy or performance as traditional methods. Not all vaccine types are compatible with newer delivery technologies such as microneedles or patches, which limits the scope of their use. The size, viscosity, and stability of certain vaccines can pose challenges when attempting to deliver them through advanced systems, leading to potential compatibility issues between the vaccine formulation and the delivery device. Device malfunction or inconsistent performance in certain settings could undermine the overall efficacy and patient safety. Continuous research and development are required to overcome these technical challenges and ensure compatibility across a wide range of vaccine types and patient demographics.

Key Market Trends

Technological Advancements in Delivery Devices

Technological innovation in vaccine delivery devices has played a critical role in transforming the way vaccines are administered. Over the past decade, advances in needle-free injection systems, microneedles, and auto-injectors have made the process of vaccination faster, less painful, and more efficient. Needle-free systems, for example, use high-pressure technology to inject vaccines through the skin without the use of a traditional needle, addressing concerns related to needle aversion and needle-stick injuries. These systems are particularly beneficial for children, elderly populations, and those with a fear of injections. Microneedles, which are tiny arrays that can painlessly penetrate the skin's outer layer, offer a minimally invasive method for vaccine delivery, providing a promising solution for improving compliance in large-scale vaccination campaigns.

These advancements in delivery technology also help improve the precision and efficiency of vaccine administration. The adoption of smart injection devices equipped with sensors and tracking technology allows for real-time monitoring of vaccination procedures, improving both patient outcomes and reporting capabilities. These technological strides are making vaccine delivery more comfortable, effective, and scalable, thus driving greater market adoption.

Government Initiatives and Funding

Government support is another key driver for the global vaccine delivery devices market. Numerous countries are investing heavily in vaccination programs to control the spread of infectious diseases, reduce healthcare costs, and promote public health. Notably, government initiatives like GAVI, the Vaccine Alliance and CEPI (Coalition for Epidemic Preparedness Innovations) have been pivotal in funding global immunization campaigns and making vaccines accessible in developing countries. These organizations focus on improving vaccine delivery infrastructure, expanding immunization coverage, and reducing vaccine inequity, ensuring that delivery devices are available and affordable for mass immunization efforts.

Many governments are allocating substantial resources to fund the research and development of advanced vaccine delivery devices. For example, the U.S. government's Operation Warp Speed led to rapid development and distribution of COVID-19 vaccines, which included support for innovative vaccine delivery solutions such as auto-injectors and needle-free systems. With governments at the forefront of pandemic preparedness, the demand for vaccine delivery devices is expected to remain high, as these devices are crucial for administering vaccines effectively and on a large scale.

Segmental Insights

Device Insights

Based on the device, the syringe-based delivery system was the fastest-growing method in the Global Vaccine Delivery Devices Market. This traditional method continues to be the dominant choice for vaccine administration due to its reliability, ease of use, and well-established infrastructure in healthcare settings worldwide. Syringes have been the standard tool for vaccine delivery for decades, and their widespread use, combined with extensive training for healthcare professionals, has solidified their dominant role in both developed and emerging markets.

Syringes are favored for their proven effectiveness, low cost, and versatility in administering a broad range of vaccines, including inactivated, live attenuated, and genetic-based vaccines. This flexibility is especially critical as new vaccines for emerging diseases like COVID-19 and Ebola are developed. The syringe-based delivery system's established infrastructure, comprehensive global supply chain, and affordability have made it a go-to method for large-scale vaccination programs, particularly in resource-constrained settings where budget is a key consideration.

Despite the rise of newer technologies like jet injectors, syringes continue to grow due to their high degree of accuracy and control, ensuring the correct dose is administered to patients. Additionally, syringes remain crucial in vaccination campaigns in regions with limited access to advanced medical technologies, further driving their dominance in the market..

Route Of Administration Insights

Based on the Route Of Administration segment, Intramuscular vaccination currently dominates the global vaccine delivery devices market due to its widespread use, effectiveness, and compatibility with a broad range of vaccines. Intramuscular (IM) vaccination involves injecting the vaccine into the muscle, typically in the upper arm or thigh, which allows for rapid absorption and immune response. This method has been the standard for the administration of many vaccines, including flu vaccines, Hepatitis B, COVID-19 vaccines, and HPV vaccines, and continues to be the preferred choice for both adults and children. The ability to deliver vaccines to a large volume of individuals through intramuscular injections, coupled with their ability to elicit robust immune responses, has made IM injections the go-to method in global vaccination campaigns.

One of the primary reasons for the dominance of intramuscular vaccination is its established role in vaccination programs worldwide. The infrastructure for IM vaccination is well established, and healthcare professionals are extensively trained in the technique, making it an efficient and reliable method for vaccine administration. With decades of usage and scientific research supporting its safety and efficacy, intramuscular injection is supported by stringent regulatory frameworks from global health organizations such as the World Health Organization (WHO) and national regulatory bodies like the U.S. Food and Drug Administration (FDA).

IM injections are well-suited for delivering vaccines that require a deep tissue injection, which ensures a larger surface area for the vaccine to be absorbed, providing a quicker immune response. Vaccines that are designed to generate long-lasting immunity, such as those for COVID-19, are often administered through IM injections because this method ensures the vaccine reaches the muscle tissue, where it can effectively interact with the immune system to generate a strong immune response. This is particularly important for protein-based vaccines and mRNA vaccines, which have been a major focus in recent years.

Regional Insights

North America dominated the global vaccine delivery devices market due to several key factors, including advanced healthcare infrastructure, robust regulatory frameworks, and significant investments in public health initiatives. The region, particularly the United States, has long been at the forefront of medical innovations and technological advancements, which has translated into strong demand for cutting-edge vaccine delivery solutions. North America's high healthcare spending, widespread access to vaccines, and strong focus on preventive healthcare have driven the adoption of various vaccine delivery devices, including syringes, auto-injectors, and needle-free systems.

One of the primary reasons for North America's dominance is its well-established healthcare infrastructure. The region boasts a large number of hospitals, outpatient clinics, vaccination centers, and pharmacies, all equipped with the necessary infrastructure to support large-scale vaccination campaigns. In addition, government programs such as the U.S. Centers for Disease Control and Prevention (CDC) and Vaccine Adverse Event Reporting System (VAERS), along with global initiatives like GAVI, have played a pivotal role in promoting vaccine accessibility and ensuring a seamless distribution of vaccines across populations. This has contributed significantly to the demand for advanced vaccine delivery systems.

The COVID-19 pandemic further accelerated the growth of the vaccine delivery devices market in North America, as the region was one of the first to roll out vaccines on a mass scale. The quick adoption of novel vaccine technologies, such as mRNA vaccines, and the need for efficient delivery methods led to increased use of innovative delivery devices, including auto-injectors and needle-free injection systems. The rapid rollout of COVID-19 vaccinations showcased North America's capacity to efficiently administer vaccines through a combination of traditional and advanced delivery devices, solidifying its leadership position in the market.

Regulatory support is another major factor contributing to North America's dominance. In the U.S., for example, regulatory bodies like the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have stringent guidelines for vaccine development and the use of vaccine delivery devices. These agencies ensure that the products meet rigorous safety standards before reaching the market, thus enhancing consumer confidence and encouraging widespread adoption. These organizations have been instrumental in approving innovative vaccine delivery devices, which have further expanded the market.

Key Market Players

Becton Dickinson & Company

Bioject Medical Technologies, Inc. (Inovio Pharmaceutical Inc.)

PharmaJet, Inc.

Vaxxas, Inc.

Gerresheimer AG

SCHOTT AG

Corium, LLC

3M Company

Croda International Plc

Meiji Holdings Co., Ltd.

Report Scope:

In this report, the Global Vaccine Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vaccine Delivery Devices Market, By Device:

Syringes
Jet Injectors

Vaccine Delivery Devices Market, By Route of Administration:

Intradermal Vaccination
Intramuscular Vaccination
Subcutaneous Vaccination

Vaccine Delivery Devices Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vaccine Delivery Devices Market.

Available Customizations:

Global Vaccine Delivery Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vaccine Delivery Devices Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Device (Syringes and Jet Injectors)
- 5.2.2. By Route Of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Vaccine Delivery Devices Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Device
- 6.2.2. By Route Of Administration
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Vaccine Delivery Devices Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Device
    - 6.3.1.2.2. By Route Of Administration
- 6.3.2. Canada Vaccine Delivery Devices Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Device
    - 6.3.2.2.2. By Route Of Administration
- 6.3.3. Mexico Vaccine Delivery Devices Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Device
    - 6.3.3.2.2. By Route Of Administration

7. Europe Vaccine Delivery Devices Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Device
- 7.2.2. By Route Of Administration
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Vaccine Delivery Devices Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Device
    - 7.3.1.2.2. By Route Of Administration
- 7.3.2. United Kingdom Vaccine Delivery Devices Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Device
    - 7.3.2.2.2. By Route Of Administration
- 7.3.3. Italy Vaccine Delivery Devices Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Device
    - 7.3.3.2.2. By Route Of Administration
- 7.3.4. France Vaccine Delivery Devices Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Device
    - 7.3.4.2.2. By Route Of Administration
- 7.3.5. Spain Vaccine Delivery Devices Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Device
    - 7.3.5.2.2. By Route Of Administration

8. Asia-Pacific Vaccine Delivery Devices Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Device
- 8.2.2. By Route Of Administration
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Vaccine Delivery Devices Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Device
    - 8.3.1.2.2. By Route Of Administration
- 8.3.2. India Vaccine Delivery Devices Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Device
    - 8.3.2.2.2. By Route Of Administration
- 8.3.3. Japan Vaccine Delivery Devices Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Device
    - 8.3.3.2.2. By Route Of Administration
- 8.3.4. South Korea Vaccine Delivery Devices Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Device
    - 8.3.4.2.2. By Route Of Administration
- 8.3.5. Australia Vaccine Delivery Devices Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Device
    - 8.3.5.2.2. By Route Of Administration

9. South America Vaccine Delivery Devices Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Device
- 9.2.2. By Route Of Administration
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Vaccine Delivery Devices Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Device
    - 9.3.1.2.2. By Route Of Administration
- 9.3.2. Argentina Vaccine Delivery Devices Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Device
    - 9.3.2.2.2. By Route Of Administration
- 9.3.3. Colombia Vaccine Delivery Devices Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Device
    - 9.3.3.2.2. By Route Of Administration

10. Middle East and Africa Vaccine Delivery Devices Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Device
- 10.2.2. By Route Of Administration
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Vaccine Delivery Devices Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Device
    - 10.3.1.2.2. By Route Of Administration
- 10.3.2. Saudi Arabia Vaccine Delivery Devices Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Device
    - 10.3.2.2.2. By Route Of Administration
- 10.3.3. UAE Vaccine Delivery Devices Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Device
    - 10.3.3.2.2. By Route Of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Becton Dickinson & Company
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Bioject Medical Technologies, Inc. (Inovio Pharmaceutical Inc.)
14.3. PharmaJet, Inc.
14.4. Vaxxas, Inc.
14.5. Gerresheimer AG
14.6. SCHOTT AG
14.7. Corium, LLC
14.8. 3M Company
14.9. Croda International Plc
14.10. Meiji Holdings Co., Ltd.